GlaxoSmithKline discontinues Flovent Rotadisk
Executive Summary
GlaxoSmithKline is discontinuing Flovent Rotadisk (fluticasone propionate inhalation powder). The decision was based "on a careful assessment of the product's current manufacturing process needs, current low product volumes utilized, and the availability of alternative therapies for the treatment of asthma," the company says in a 1"Dear Doctor" letter. Supplies of Flovent Rotadisk, which represents less than 1% of the franchise's sales, will begin to be depleted in September. GSK's letter highlights the continued availability of Flovent inhalation aerosol. Flovent is also approved, but not marketed, in Diskus and HFA formulations...
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.